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Introduction: There is good evidence to suggest that
chronic obstructive pulmonary disease (COPD)
increases the risk of ischaemic heart disease, in
particular myocardial infarction (MI). The relationship
between stroke and COPD, however, is not as well
established, and studies conducted to date have
generated conflicting results.
Methods and analysis: MEDLINE and Embase will
be searched for relevant articles using a prespecified
search strategy. We will target observational studies
conducted in the general population that employ either
a longitudinal cohort or case–control study design to
estimate ORs, HRs or incident rate ratios for the
association between COPD and a subsequent first
stroke. Both stages of screening, title and abstract
followed by full-text screening, will be conducted
independently by two reviewers. The Population,
Exposure, Comparator, Outcomes, Study characteristics
(PECOS) framework will be used to systematise the
process of extracting data from those studies meeting
our selection criteria. Study quality will be assessed
using an adapted version of the Newcastle-Ottawa risk
of bias tool. The data extraction and the risk of bias
assessment will also be conducted in duplicate. A
meta-analysis will be considered if there is sufficient
homogeneity across selected studies or groups of
studies. If a meta-analysis is not justified, a narrative
synthesis will be conducted. Selected Grading of
Recommendations, Assessment, Development and
Evaluation (GRADE) criteria will be used to assess the
quality of the cumulative evidence.
Dissemination: Currently ranking second and fourth
in the list of global causes of mortality, respectively,
stroke and COPD are important non-communicable
diseases. With this review, we hope to clarify some of
the current uncertainty that surrounds the COPD–stroke
relationship and in turn improve understanding of the
nature of the role of COPD in comorbid stroke.
Prospero registration number: CRD42016035932.
BACKGROUND
Rationale
Chronic obstructive pulmonary disease
(COPD) is a common debilitating inﬂamma-
tory lung condition characterised by
progressive airﬂow limitation and concomi-
tant respiratory symptoms. Prevalence esti-
mates vary between countries but generally
lie in the range 5–10%.1 Rates of COPD rise
steeply with increasing age and are generally
higher in men than in women. Smoking is
considered to be the main risk factor, but
exposure to airborne irritants and genetic
predisposition are likely contributory
factors.1
Comorbidities are a deﬁning feature of
COPD. More than 95% of patients with
COPD have at least one comorbidity and
over 50% have four or more coexisting dis-
eases.2 Cardiovascular diseases (CVDs) are
especially prevalent among patients with
COPD and are considered to contribute sub-
stantially to COPD disease progression, low
quality of life, poor clinical outcomes and all-
cause mortality in this group of patients.3
Both cerebrovascular disease (stroke) and
ischaemic heart disease (IHD) have been
Strengths and limitations of this study
▪ This review benefits from a comprehensive
search strategy, designed to retrieve as many
articles relevant to our primary and secondary
research questions as possible. In particular, we
have broadened our scope to include studies
which examine the relationship between impaired
lung function and stroke, as well as that between
a chronic obstructive pulmonary disease (COPD)
diagnosis and stroke.
▪ This review is not unique in the sense that other
researchers have examined the evidence linking
COPD and stroke. However, it does seek to build
on and extend previous work by including a
number of new studies and by distinguishing
prevalent and incident stroke events more expli-
citly than has hitherto been attempted.
▪ The main limitation, inherent in observational
studies which rely on administrative healthcare
databases, is uncertainty in the validity of the
ascertainment of the exposure (diagnosis of
COPD) and the outcomes (stroke case
definition).
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shown to be associated with COPD.4–7 Whereas the
latter association has been well documented and there
is, for instance, good evidence to suggest that COPD
increases the risk of myocardial infarction (MI) approxi-
mately twofold,6 that between stroke and COPD has not
been subject to the same level of scrutiny. This is despite
the fact that stroke is one of the most common causes of
death and severe disability worldwide, second only to
IHD.8
Those studies which have examined the association
between COPD and stroke risk have generated conﬂict-
ing results.9–11 Attempts have been made to review the
available evidence linking COPD and stroke,4 6 12 13 typ-
ically as part of broader systematic reviews looking a
range of CVD outcomes. In a largely narrative review of
cohort and case–control studies, Müllerova et al4 were
unable to ﬁnd sufﬁcient cumulative evidence to support
the hypothesis that COPD is an independent risk factor
for stroke. More recently, Chen et al6 have attempted to
quantify the magnitude of the associations between CVD
outcomes and COPD, based on a much larger evidence
base (29 studies) and using a more rigorous review
methodology. For stroke outcomes, a meta-OR of 1.32
(95% CI 0.99 to 1.76; 16 datasets) was calculated, provid-
ing only weak evidence for an increased risk for all
stroke in COPD. However, as the authors themselves
acknowledge, their analysis is compromised by a heavy
reliance on cross-sectional studies which restricts assess-
ment of the temporality of the association.
In the present systematic review, it is our intention to
examine the evidence base linking stroke and COPD. By
extending the work of previous reviewers in a number of
key respects, we hope to clarify some of the uncertainty
that currently surrounds the nature of the relationship
between COPD and the risk of stroke. In the ﬁrst
instance, we intend to expand the evidence base for the
review by including a number of recently published
large, population-based observational studies. These new
studies are likely to provide valuable insight given that
they are longitudinal in nature and also consider, for the
ﬁrst time, outcomes by stroke subtype (ie, ischaemic
(atherothrombotic, cardioembolic and lacunar infarcts)
or haemorrhagic (intracerebral and subarachnoid)
stroke). The latter is of particular interest given the pos-
sibility that COPD may increase the risk for certain types
of stroke more than others. Arboix et al,14 for example,
report a signiﬁcant association between COPD and
atherothrombotic ischaemic strokes but not cardioem-
bolic strokes, lacunar infarcts or ischaemic strokes of
unusual aetiology.
In addition to exploring the COPD–stroke association
by stroke subtype, we will attempt to group studies by
study design, separating those cross-sectional studies that
estimate prevalence from studies that estimate stroke risk
(as incident events). Third, we will also review the evi-
dence linking stroke risk to lung function, as measured
by forced vital capacity (FVC), forced expiratory volume
in 1 second (FEV1), and the ratio, FEV1/FVC.
Objectives
The primary aim of the systematic review is to determine
whether people with COPD are at greater risk of a subse-
quent cerebrovascular event (stroke) than those without
COPD.
Secondary research questions include the following:
▸ Is there any evidence that the association between
COPD and stroke varies with age, sex, smoking
history, medication history and/or type of stroke (eg,
haemorrhagic vs ischaemic stroke)?
▸ Is COPD an independent risk factor for stroke?
▸ Is stroke risk modiﬁed in particular COPD pheno-
types, for example, in frequent exacerbators and/or
in those with more severe disease?
▸ Is the magnitude of the association between COPD
and subsequent stroke generally lower, higher or
similar to that observed between COPD and MI?
METHODS
This protocol has been prepared using the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses Protocols (PRISMA-P) guidelines.15
Eligibility criteria
Study design/characteristics: Our target will be observational
studies that use either a longitudinal cohort (prospective
and retrospective) or a case–control study design. While
recognising the limitation of cross-sectional study designs
in terms of assessment of temporality, we will also con-
sider cross-sectional studies which estimate stroke preva-
lence, and/or ORs for stroke, in COPD versus COPD-free
patient groups. We will also include studies which are sec-
ondary analyses of a randomised control trial (RCT)
where these meet our other inclusion criteria.
Participants: Our study populations will ideally be
drawn from the general adult population but restricted
to those aged 35 years and over. If necessary and appro-
priate, studies involving a hospitalised patient population
will also be included. Studies conducted post 1980, from
any world region and reported in any language will be
considered as eligible.
Animal studies will not be included.
Exposure: The primary exposure of interest is COPD.
Thus, studies involving an exposed participant group
whose members have a conﬁrmed clinical diagnosisi of
COPD will be included in the review. Depending on the
number of studies retrieved, we will also consider studies
in which COPD diagnosis relies on self-report.
Studies in which the exposure status is assessed in
terms of spirometry alone will also form part of the
iAccording to GOLD, a diagnosis of COPD should be considered in
any patient who has dyspnoea, chronic cough or sputum production
and a history of exposure to known risk factors. A clinical diagnosis
requires conﬁrmation by spirometry: a postbronchodilator FEV1/FVC
ratio of <0.7 is considered indicative of airway obstruction and thus
COPD.1
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review. In adults with ‘normal’ lung function, the value
of the FEV1/FVC ratio lies between 0.7 and 0.8; a value
of <0.7 indicates impaired lung function, and more pre-
cisely, airﬂow obstruction. Other measures of lung func-
tion, FEV1 and FVC, are less speciﬁc and low values can
indicate either obstructed or restricted airﬂow.
Comparators (controls): In order to be eligible for inclu-
sion, studies must compare outcomes in a group of
exposed individuals (people with a diagnosis of COPD
or evidence of impaired lung function) with a group of
unexposed individuals, that is, people without COPD or
normal lung function.
Outcomes: Studies will be included in the review if one
of the primary outcomes is objective or self-reported
stroke. A stroke is conventionally deﬁned as a focal dis-
turbance of cerebral function of vascular origin lasting
more than 24 hours. When the disturbance is of a transi-
ent nature, and does not appear to cause lasting neuro-
logical damage and clinical symptoms, it is referred to as
a transient ischaemic attack or a TIA. Strokes are further
subdivided into ischaemic and haemorrhagic strokes.
Accounting for 85% of all strokes, ischaemic strokes are
by far the more common. Haemorrhagic strokes, while
less prevalent, are associated with higher mortality rates
(30–50%).
In the case of those studies which meet our primary
inclusion criteria, and for which data are available, we will
assess a number of additional outcomes. Secondary out-
comes of interest include MI and stroke subtypes. We
will also report the results of any stratiﬁed analyses
which estimate stroke risk in subpopulations of potential
interest.
Information sources
The two main biomedical-related databases, MEDLINE
(Ovid interface, 1948 onwards) and Embase (Ovid inter-
face, 1980 onwards), will be searched for potentially rele-
vant articles using predeﬁned search strategies (see Search
strategy). To ensure research saturation, the electronic
database search will be supplemented by a manual search
of the reference lists of all included studies to check for
additional potentially relevant studies.
The International Prospective Register of Systematic
Reviews (PROSPERO) will also be periodically checked
for ongoing and completed systematic reviews that deal
with COPD and comorbidities.
Search strategy
Literature search strategies will be based on both MeSH
terms (Medical Subject Headings) and free text (natural
language) searching using an appropriate set of key
words to delimit the concepts ‘COPD’ and ‘stroke’.
These searches will be combined using the AND
Boolean logic operator.
The list of proposed search terms will be reviewed by a
number of people with medical knowledge and any
necessary adjustments made prior to running the
search. The search strategy will be developed in the ﬁrst
instance for MEDLINE and then adapted for use with
Embase. No search ﬁlters will be applied. The proposed
search terms are listed in table 1.
The literature searches will be updated at the end of
the review exercise.
Study records
Data management: Literature search results will be
uploaded to EndNote (V.7) and duplicate records
removed.
Selection process: The selection of studies for inclusion
in the review will be conducted in two stages. First, titles
and abstracts of all records identiﬁed by the database
searches will be screened by the primary researcher
against the predeﬁned eligibility criteria (see above) in
order to identify a subset of potentially relevant studies.
A second reviewer will repeat this exercise on a propor-
tion of records (approximately half) and any discrepan-
cies resolved by discussion. To reduce the risk of missing
potentially relevant studies, a deliberately lenient
approach will be adopted for this ﬁrst level of screening
(by title and abstract).
We will obtain full reports for all titles that appear to
meet our eligibility criteria, or where there is uncer-
tainty. Full text screening will be also conducted by two
reviewers, with the primary researcher screening all
reports and the second reviewer approximately one half.
Online supplementary material will be consulted if the
information provided in the main published article is
insufﬁcient to assess whether or not the inclusion cri-
teria are met. Any discrepancies will be resolved by dis-
cussion and/or consultation with a third reviewer with
speciﬁc expertise in COPD. A record will be kept of the
reasons for rejection of articles during the full-text
screening process.
Table 1 Search terms (provisional)
Concept Search terms
COPD MeSH terms: exp Pulmonary Disease, Chronic
Obstructive/; Lung Diseases, Obstructive/Free
text terms: COPD; COAD; COBD; AECB;
emphysema; chronic bronchitis; obstructive
(pulmonary or lung or airway or airflow or
bronchitis or respiratory) disease; lung or
respiratory or ventilatory) function
Stroke MeSH terms: exp Stroke/; Stroke, Lacunar/;
Free text terms: stroke; CVA; TIA;
cerebrovascular (disease or event or accident
or attack or injury); cerebral ischaemia;
transient ischaemic attack; ischaemic stroke
(atherothrombotic, cardioembolic, lacunar
infarction); haemorrhagic stroke (intracerebral,
subarachnoid)
AECB, acute exacerbation of chronic bronchitis; COAD, chronic
obstructive airways disease; COBD, chronic obstructive bronchial
disease; COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; TIA, transient ischaemic attack.
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Data extraction: Information will be extracted from all
selected studies using a prespeciﬁed data extraction
form designed by the primary reviewer (see online
supplementary table S1). The form will be piloted on
the ﬁrst six selected studies and reﬁned as necessary.
Online supplementary material will be consulted and/
or authors contacted if the information provided in the
original published articles is insufﬁcient to complete the
extraction.
As with screening, data extraction will be carried out
in duplicate on a proportion of selected records to
reduce the risk of errors and introducing bias (around a
quarter). Similarly, any discrepancies will be resolved by
discussion and/or consultation with the third reviewer.
Data items
We will use the Population, Exposure, Comparator,
Outcomes, Study characteristics (PECOS) framework to
systematise our data extraction. Within each of these ﬁve
domains, information will be recorded on the following
items:
▸ Study characteristics: setting, design, period of study,
aims and objectives;
▸ Population: characteristics of the study population
(including size, sex and age distribution, ethnicity),
recruitment and sampling methods, inclusion/exclu-
sion criteria);
▸ Exposure: exposure status deﬁnition and identiﬁca-
tion, number of exposed subjects, any exclusions;
▸ Comparators: identiﬁcation and deﬁnition of unex-
posed individuals, number of unexposed subjects, any
exclusions;
▸ Outcomes: deﬁnition and identiﬁcation of primary
(stroke) and secondary outcomes (stroke subtypes,
MI), number of subjects, any exclusions, length of
follow-up.
In terms of the effect estimates for the association
between COPD and stroke, we will record both the
unadjusted and the maximally adjusted estimates.
Details of the covariates measured and adjusted for will
also be noted. Results of any additional stratiﬁed ana-
lyses, for example, by age group, gender or severity of
COPD, will be itemised when these have been con-
ducted. If stratiﬁed effect estimates of interest are not
reported in the published article, this information will
be sought from the study authors.
Outcomes and prioritisation
The primary clinical outcome of interest is ﬁrst recorded
stroke post a COPD diagnosis. We will prioritise those
studies with a longitudinal study design that calculate
effect estimates as either HRs or incidence rate ratios,
but will also consider those studies that report ORs if it
can be determined that subjects had not had a stroke
event prior to the start of the study period.
Outcomes disaggregated by type of stroke—ischaemic
(atherothrombotic, cardioembolic, lacunar infarct),
haemorrhagic (intracerebral, subarachnoid) and/or TIA
—will be recorded for those studies which report such
information. When risk of MI is also reported for the
same cohort of patients, this will also be noted.
Risk of bias assessment (in individual studies)
There are several established methods and tools for
assessing the methodological quality of individual
studies.16 However, the majority of these have been
designed with the needs of RCT and healthcare inter-
ventions in mind and have limited application to obser-
vational studies. For this reason, we plan to devise our
own risk of bias assessment tool, drawing on the
Newcastle-Ottawa scale17 and structured around three
main sources of bias (domains):
▸ selection of participants;
▸ measurement of variables (exposures, outcomes and
covariates);
▸ control of confounding.
Each component of our chosen domains will be
assigned a risk of bias category from the following: ‘mod-
erate to high risk of bias’, ‘unclear risk of bias’ or ‘low
risk of bias’. We will consider each component of our
tool separately and will not attempt to assign our
included studies an overall score.
Risk of bias assessment will be conducted independ-
ently by two reviewers on a quarter of the selected studies
and disagreements will be resolved in the ﬁrst instance by
discussion and then through consultation with a third
reviewer. On completion of this process, the remaining
studies will be assessed for risk of bias by one reviewer.
Data synthesis
For the purposes of data synthesis, we will group studies
according to both outcome deﬁnition (ie, prevalent vs
incident stroke) and exposure deﬁnition, that is to say, we
will distinguish studies which evaluate stroke risk in
COPD versus non-COPD patients and those that
compare the incidence of stroke in people with impaired
lung function with those with normal lung function (as
measured by FVC, FEV1, or FEV1/FVC). Our primary
analysis will consider all strokes (as a composite
outcome); depending on the number of retrieved
studies, analyses by stroke subtype will be also conducted.
Depending on the characteristics of the included studies,
we will consider stratifying our results according to one
or more additional criteria, for instance, by population
(general vs hospitalised) and exposure ascertainment
(physician diagnosis vs self-report).
If we ﬁnd our included studies (or groups of studies)
are sufﬁciently homogenous in terms of design, study
population and outcomes, we will conduct a
meta-analysis (using inverse variance weighting) to calcu-
late a pooled effect estimate. We will use the I2 statistic
to assess the level of statistical heterogeneity and to
guide our choice of model (ﬁxed or random effects
model). If however we ﬁnd that level of heterogeneity
(I2 >75%) precludes such an approach, a narrative syn-
thesis will be conducted, to include summary tables
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detailing study characteristics, participants, exposure
status and outcomes, and effect estimates.
Risk of bias in meta-analysis
Given sufﬁcient numbers of studies, we will use funnel
plots to assess the likelihood of outcome reporting bias
(publication and other reporting biases) and a Begg’s test
to test for asymmetry. If however this is not possible we will
discuss possible sources of bias across studies and bear
this limitation in mind when drawing our conclusions.
Confidence in cumulative evidence
The quality of evidence for our primary and secondary
research questions will be assessed using those domains
of the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) guidelines18 that
are pertinent to observational studies, notably those
relating to methodological ﬂaws within the component
studies and the consistency of results across different
studies. Additional domains may be considered if
deemed appropriate. Strength of evidence will be
judged as ‘high’ (further research is unlikely to change
our conclusion), ‘moderate’ (further research is likely to
alter our conclusion) or ‘low’ (further studies are
required to answer the research question with a high
degree of conﬁdence/increase conﬁdence).
ETHICS AND DISSEMINATION
Ethical review is not required as this study is a systematic
review. It is our intention to submit the results of our
review for peer-reviewed publication and to present our
ﬁndings at national and international meetings and
conferences.
Both stroke and COPD are important chronic non-
communicable diseases, currently ranking second and
fourth in the list of causes of global mortality, respect-
ively.8 With this review, we hope to contribute to the
existing knowledge base for both conditions, but princi-
pally to an improved understanding of the nature of the
role of COPD in comorbid stroke.
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